1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Physician Views: Are dermatologists ready for a new class of psoriasis therapies?

Physician Views: Are dermatologists ready for a new class of psoriasis therapies?

  • January 2015
  • ID: 2802258
  • Format: PDF
  • By Firstword Pharma

Summary






Novartis has become the first player to bring to market an interleukin-17A inhibitor, most recently announcing on Monday that the European Commission approved Cosentyx for the treatment of moderate-to-severe plaque psoriasis. Approval in the US market for the same indication is also expected in the near future.

With regulators on both sides of the Atlantic providing positive assessment of Cosentyx prior to full approval, a green-light for the product comes as little surprise. Indeed, focus among analysts in recent months has switched to the commercial opportunity for Cosentyx.

Analysts at UBS argued in December that among Novartis investors, Cosentyx continues to fly under the radar despite its near-term launch (a status shaped by high levels of focus on the approval and launch of LCZ696 for heart failure, they add). They note, however, that Novartis could have two potential blockbuster launches on its hands in 2015 if both Cosentyx and LCZ696 live up to potential.

Key data for Cosentyx appears to be the Phase IIIb study results top-lined by Novartis in December which demonstrated superiority versus Johnson & Johnson's IL-12/IL-23 inhibitor Stelara. Stelara has emerged as the new standard of care among biologic therapies indicated to treat moderate-to-severe psoriasis thanks to better efficacy, cleaner safety and more convenient dosing relative to the heavily entrenched anti-TNF agents (i.e. Humira, Enbrel, Remicade). As such, Stelara has emerged as one of the industry's fastest growing drugs (ViewPoints: New data may vault Novartis' Cosentyx into lead among competitors vying for Stelara's crown)).

Cosentyx is not the only IL-17A inhibitor to have demonstrated superiority versus Stelara, with this feat matched by Amgen and AstraZeneca's co-developed competitor drug brodalumab. Crucially, however, analysts currently estimate that Novartis has an approximate 12-month head-start (and thus IL-17A inhibitor monopoly position) over brodalumab, which is not due to be filed until the second half of 2015. A third IL-17A inhibitor, Eli Lilly's ixekizumab, is in Phase III development, but has not been studied head-to-head versus Stelara; a decision that is likely to weaken its commercial profile, at least initially.

In the psoriasis setting (the IL-17A inhibitors are being studied across additional indications), the next 12 months could therefore be critical in shaping the trajectory of secukinumab and the class as a whole.








In response to EU approval, we are polling EU5 and US-based dermatologists with the following questions…


How aware are you of secukinumab?
How impressive do you consider Phase III data for secukinumab to be?
Excluding the consideration of price, how would you describe your anticipated usage levels of secukinumab in its first 12 months of availability among newly diagnosed patients with moderate-to-severe plaque psoriasis for whom treatment with a biologic is appropriate?
Excluding the consideration of price, how would you describe your anticipated usage levels of secukinumab in its first 12 months of availability among patients with moderate-to-severe plaque psoriasis who are being switched from another biologic therapy?
How important a role will your experience with current biologics and the established safety profiles of these products play in limiting and/or slowing uptake of secukinumab and other products in the IL-17a class?


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020

Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Tyrosine Protein Kinase JAK1 - Pipeline Review, H1 2020SummaryTyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 42 molecules. Out of which approximately ...

Aryl Hydrocarbon Receptor - Pipeline Review, H2 2019

Aryl Hydrocarbon Receptor - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Aryl Hydrocarbon Receptor - Pipeline Review, H2 2019SummaryAryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 26 molecules. Out ...

Tyrosine Protein Kinase ITKTSK - Pipeline Review, H2 2019

Tyrosine Protein Kinase ITKTSK - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Tyrosine Protein Kinase ITKTSK - Pipeline Review, H2 2019SummaryTyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase ...


ref:plp2015

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on